Skip to content

Submit a clinical trial (or an early access programme)

Are you conducting a new clinical trial or do you need to update a study already published on our platform? Use this form to submit a new study or request changes to an existing entry. All submissions are reviewed by SPOG (Swiss Paediatric Oncology Group) to ensure relevance for families.

Important: This platform is designed for affected families. Please use clear, accessible language that non-specialists can understand. The platform operates in German, French, Italian, and English. Submitters are responsible for providing translations. If a translation is missing, “translation not (yet) available” will appear in that language version. Submitters are fully responsible for the accuracy of the content and must have permission to publish or update the information. Please use the exact text as approved by the responsible ethics committees, without any modifications.


Eligibility criteria

    • Type of trial: Interventional clinical trial (or early access programme of a novel anti-cancer drug)
    • Trial intervention: Anti-cancer or supportive therapy (pharmacological or non-pharmacological)
    • Patient population: Includes pediatric patients with cancer
    • Participating sites: One or more SPOG sites
    • To be considered for publication on this platform, a clinical trial should be listed on HumRes (www.humanforschung-schweiz.ch) and/or ClinicalTrials.gov

Exceptions (e.g. non-SPOG sites only) can be discussed on a case-by-case basis.

 

Person submitting this study entry

Please indicate the contact person submitting this form. We will contact this person for any questions related to the submission, and to confirm publication on the platform. This information will not be published on the platform and will only be used for internal communication.

Study information (for public display)

Enter the official acronym, if available (e.g. AIEOP-BFM ALL 2017). If none, write “n/a”.

Short, clear title for parents. Indicate cancer type and line of treatment (e.g. first-line, relapse). Max. 1000 characters.

Brief summary of the study in layman's langugage with information about line of treatment

Brief summary of the study in layman's langugage with information about line of treatment

Brief summary of the study in layman's langugage with information about line of treatment

Lay summary of the protocol in English

Short, clear summary for parents: purpose, cancer type, treatment line, and key procedures. Use simple language without specialised terminology: "like the flip of a coin" instead of "randomised", "heart disease" instead of "cardiopathy", "neither you nor your doctor will know what treatment you receive" instead of "double blind" etc. Please use the exact lay summary text as approved by the responsible ethics committees, without any modifications.

Diagnosis

Leukaemia, lymphoma and bone marrow disease

Brain and spinal cord tumors

Solid
tumors

Open sites in Switzerland

Thank you for your submission!

Your study has been submitted successfully. We will review it and get back to you soon.

Return to Home